Acetyl-CoA carboxylase

From WikiMD's Medical Encyclopedia

Revision as of 04:44, 18 February 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Acetyl-CoA carboxylase

Biotin carboxylase structure
Biotin carboxyl carrier protein
Carboxytransferase structure
Mechanism of acetyl-CoA carboxylase
Regulation of acetyl-CoA carboxylase

Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the carboxylation of acetyl-CoA to form malonyl-CoA. This reaction is the first committed step in fatty acid synthesis and is a key regulatory point in the metabolic pathway.

Structure[edit]

Acetyl-CoA carboxylase is a multi-domain enzyme that consists of three main functional components: the biotin carboxylase (BC) domain, the biotin carboxyl carrier protein (BCCP) domain, and the carboxytransferase (CT) domain. The BC domain catalyzes the ATP-dependent carboxylation of biotin, which is then transferred to the BCCP domain. The CT domain catalyzes the transfer of the carboxyl group from biotin to acetyl-CoA, forming malonyl-CoA.

Function[edit]

The primary function of acetyl-CoA carboxylase is to provide malonyl-CoA for the synthesis of long-chain fatty acids. Malonyl-CoA is also an important regulator of fatty acid oxidation, as it inhibits carnitine palmitoyltransferase I (CPT1), the enzyme responsible for transporting fatty acids into the mitochondria for oxidation.

Regulation[edit]

Acetyl-CoA carboxylase is regulated by multiple mechanisms, including allosteric regulation, covalent modification, and changes in gene expression. The enzyme is activated by citrate, which promotes polymerization of the enzyme into its active form, and inhibited by palmitoyl-CoA, which promotes depolymerization. Phosphorylation by AMP-activated protein kinase (AMPK) and other kinases inactivates ACC, while dephosphorylation by protein phosphatases activates it.

Clinical significance[edit]

Dysregulation of acetyl-CoA carboxylase activity is associated with metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Inhibitors of ACC are being investigated as potential therapeutic agents for these conditions.

Related pages[edit]

Gallery[edit]

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.